Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 114Neoplasms 28Lung Neoplasms 24Non-Squamous Non-Small Cell Lung Cancer 21Pancreatic Neoplasms 13Colorectal Neoplasms 6Neoplasm Metastasis 5Breast Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Lymphoma 3Thoracic Neoplasms 2Solid Tumors 2Recurrence 2Neoplasms by Site 2Lung Diseases 2Familial ependymoma 2Ependymoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Bronchial Neoplasms 2Advanced Solid Tumors 2Vascular Diseases 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Smoking 1Small Cell Lung Carcinoma 1

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × Erlotinib Hydrochloride × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡